- Home
- MYGN vs MCS Comparison
MYGN vs MCS Comparison
Compare MYGN & MCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- MCS
- Stock Information
- Founded
- MYGN 1991
- MCS 1935
- Country
- MYGN United States
- MCS United States
- Employees
- MYGN N/A
- MCS N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- MCS Movies/Entertainment
- Sector
- MYGN Health Care
- MCS Consumer Discretionary
- Exchange
- MYGN Nasdaq
- MCS Nasdaq
- Market Cap
- MYGN 423.1M
- MCS 467.8M
- IPO Year
- MYGN 1995
- MCS N/A
- Fundamental
- Price
- MYGN $6.02
- MCS $15.75
- Analyst Decision
- MYGN Hold
- MCS Strong Buy
- Analyst Count
- MYGN 13
- MCS 4
- Target Price
- MYGN $13.50
- MCS $24.75
- AVG Volume (30 Days)
- MYGN 2.4M
- MCS 298.2K
- Earning Date
- MYGN 08-05-2025
- MCS 08-01-2025
- Dividend Yield
- MYGN N/A
- MCS 1.85%
- EPS Growth
- MYGN N/A
- MCS N/A
- EPS
- MYGN N/A
- MCS 0.47
- Revenue
- MYGN $832,900,000.00
- MCS $734,999,000.00
- Revenue This Year
- MYGN N/A
- MCS $12.99
- Revenue Next Year
- MYGN $6.64
- MCS $4.39
- P/E Ratio
- MYGN N/A
- MCS $32.34
- Revenue Growth
- MYGN 3.83
- MCS 13.65
- 52 Week Low
- MYGN $3.76
- MCS $13.70
- 52 Week High
- MYGN $29.30
- MCS $23.16
- Technical
- Relative Strength Index (RSI)
- MYGN 62.34
- MCS 50.00
- Support Level
- MYGN $5.23
- MCS $14.96
- Resistance Level
- MYGN $6.07
- MCS $15.36
- Average True Range (ATR)
- MYGN 0.39
- MCS 0.45
- MACD
- MYGN 0.05
- MCS 0.10
- Stochastic Oscillator
- MYGN 81.27
- MCS 95.29
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About MCS Marcus Corporation (The)
Marcus Corp is engaged in two business segments, which are movie theatres and Hotels and Resorts. The movie theatres segment operates multiscreen motion picture theatres in Wisconsin, Illinois, Iowa, Minnesota, Missouri, Nebraska, North Dakota, Ohio and others, a family entertainment center in Wisconsin and a retail center in Missouri; Hotels and Resorts segment owns and operates full-service hotels and resorts in Wisconsin, Illinois, and Nebraska and manages full-service hotels, resorts and other properties in Wisconsin, Minnesota, Texas, Nevada, California, and North Carolina. It generates maximum revenue from the Theatres segment.